Penumbra, Inc. (PEN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Devices Branche. Der Hauptsitz des Unternehmens ist in Alameda, CA, United States. Der aktuelle CEO ist Adam Elsesser.
PEN hat IPO-Datum 2015-09-18, 4,500 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $13.04B.
Penumbra, Inc. is a medical device company headquartered in Alameda, California, that designs, develops, manufactures, and markets innovative vascular intervention and neurosurgical products globally. The company specializes in aspiration-based thrombectomy systems for mechanical clot removal, neurovascular embolization coiling systems for treating aneurysms, and neurovascular access systems, marketed under brands including Penumbra System, Penumbra Coil, and Neuron. Its product portfolio also encompasses neurosurgical aspiration tools, peripheral embolization devices, microcatheters, and occlusion devices, along with immersive technology solutions for patient rehabilitation. Penumbra distributes its products through direct sales teams and distributor networks to serve the interventional neuroradiology, neurosurgery, and vascular surgery markets worldwide.
